The National Advertising Division could become more influential in prescription drug advertising disputes going forward as the self-regulatory group builds and leverages relationships with social media platforms and federal agencies.
Speaking at the recent DIA Advertising and Promotion Regulatory Affairs Conference, NAD VP Laura Brett talked about the group’s burgeoning relationships with online platforms and regulatory agencies like the US Food and Drug Administration, the impact of its advertising dispute referrals to
Key Takeaways
-
NAD is establishing relationships with social media platforms to remove disputed ads when companies fail to comply with its decisions or refuse to participate in the review process.
-
The group also is trying to demonstrate the value of self-regulation to the FDA